{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T10:25:13Z","timestamp":1770546313333,"version":"3.49.0"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Appropriate exposure to posaconazole (PSZ) has been limited until the recent approval of the delayed-release oral tablet formulation. Our goal was to determine the exposure obtained by using the standard dose of 300 mg once a day in lung transplant (LT) patients, including patients with cystic fibrosis (CF). PSZ trough concentrations (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>0<\/jats:sub>\n            ) were determined using a liquid chromatography-tandem mass spectrometry assay. Indicative thresholds of interest were &lt;0.7 mg\/liter for prophylaxis and 1 to 3 mg\/liter for cure. The tacrolimus (TRL) and everolimus (ERL)\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>0<\/jats:sub>\n            measured during PSZ exposure were also collected. The interaction with proton-pump inhibitors (PPI) was evaluated. We recorded the results for 21 CF patients with LT (CFLT patients), 11 non-CF patients with LT (NCFLT patients), and 27 nontransplant (NT) patients in pneumology departments. The weights of the NCFLT, CFLT, and NT patients were 59.2 \u00b1 8.4, 48.8 \u00b1 8.4, and 63.7 \u00b1 16.6 kg, respectively (\n            <jats:italic>P<\/jats:italic>\n            = 0.001* [asterisk means that statistical test is significant]), and the PSZ\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>0<\/jats:sub>\n            exposures for these patients were 1.9 \u00b1 1.5, 1.1 \u00b1 0.8, and 2.4 \u00b1 1.8 mg\/liter, respectively (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.00001*). More than 60% of the concentrations were in the therapeutic range. In CFLT patients, the administration of one 300-mg PSZ tablet quickly achieved an exposure similar to that achieved with the PSZ oral suspension formulation (OSF) administered 3 or 4 times a day for several months. The TRL\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>0<\/jats:sub>\n            \/dose ratio (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>0<\/jats:sub>\n            \/\n            <jats:italic>D<\/jats:italic>\n            ) was 7.4 \u00b1 4.4 mg\/liter with PSZ tablets, whereas it was 4.6 \u00b1 0.8 mg\/liter with the PSZ oral solution (\n            <jats:italic>P<\/jats:italic>\n            = 0.034*). The ERL\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>0<\/jats:sub>\n            \/\n            <jats:italic>D<\/jats:italic>\n            was similar with both formulations. PPI had no impact on the PSZ concentration (1.49 \u00b1 1.07 mg\/liter without PPI versus 1.33 \u00b1 1.17 mg\/liter with PPI;\n            <jats:italic>P<\/jats:italic>\n            = 0.4134*). Despite the high levels of exposure, PSZ remained well tolerated (one case of diarrhea and one case of fatigue were reported). PSZ tablet administration allows satisfactory exposure, even in CFLT patients, with a dosage lower than that of the PSZ OSF. This once-a-day formulation was not impacted by PPI, which are extensively used in CF patients.\n          <\/jats:p>","DOI":"10.1128\/aac.02061-17","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T20:35:12Z","timestamp":1515184512000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":20,"title":["Posaconazole Tablets in Real-Life Lung Transplantation: Impact on Exposure, Drug-Drug Interactions, and Drug Management in Lung Transplant Patients, Including Those with Cystic Fibrosis"],"prefix":"10.1128","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3113-7301","authenticated-orcid":false,"given":"Manon","family":"Launay","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacology and Toxicology, European Hospital Georges Pompidou-APHP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Roux","sequence":"additional","affiliation":[{"name":"Pneumology, Adult Cystic Fibrosis Center and Lung Transplantation Department, Foch Hospital, Suresnes, France"},{"name":"Universit\u00e9 Versailles Saint\u2013Quentin, Versailles, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Beaumont","sequence":"additional","affiliation":[{"name":"Pneumology, Adult Cystic Fibrosis Center and Lung Transplantation Department, Foch Hospital, Suresnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Douvry","sequence":"additional","affiliation":[{"name":"Pneumology, Adult Cystic Fibrosis Center and Lung Transplantation Department, Foch Hospital, Suresnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucien","family":"Lecuyer","sequence":"additional","affiliation":[{"name":"Thoracic Transplantation, European Hospital Georges Pompidou-APHP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Douez","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Toxicology, European Hospital Georges Pompidou-APHP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Picard","sequence":"additional","affiliation":[{"name":"Pneumology, Adult Cystic Fibrosis Center and Lung Transplantation Department, Foch Hospital, Suresnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Grenet","sequence":"additional","affiliation":[{"name":"Pneumology, Adult Cystic Fibrosis Center and Lung Transplantation Department, Foch Hospital, Suresnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Jullien","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Toxicology, European Hospital Georges Pompidou-APHP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Boussaud","sequence":"additional","affiliation":[{"name":"Thoracic Transplantation, European Hospital Georges Pompidou-APHP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Guillemain","sequence":"additional","affiliation":[{"name":"Thoracic Transplantation, European Hospital Georges Pompidou-APHP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliane M.","family":"Billaud","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Toxicology, European Hospital Georges Pompidou-APHP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","volume-title":"Noxafil (posaconazole) oral suspension, summary of product characteristics","author":"Merck Sharp & Dohme Limited","year":"2012","unstructured":"Merck Sharp & Dohme Limited. 2012. Noxafil (posaconazole) oral suspension, summary of product characteristics. Merck Sharp & Dohme Limited, Hertfordshire, United Kingdom."},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2011010"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2001.003003128.x"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000371"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.28"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2016.01.007"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05000-14"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.03.021"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12389"},{"key":"e_1_3_1_11_2","volume-title":"Report EMA\/159150\/2014","author":"European Medicines Agency, Committee for Medicinal Products for Human Use","year":"2014","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. 2014. Assessment report. Noxafil. Report EMA\/159150\/2014. European Medicines Agency, London, United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000610\/WC500168187.pdf."},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks268"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03680.x"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.12.1730"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/0003088-200847120-00003"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02931-15"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2010.505203"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2017.03.009"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.11.233"},{"key":"e_1_3_1_20_2","volume-title":"EMA warns that Noxafil tablets and oral suspension have different doses and are not interchangeable","author":"European Medicines Agency","year":"2016","unstructured":"European Medicines Agency. 2016. EMA warns that Noxafil tablets and oral suspension have different doses and are not interchangeable. European Medicines Agency, London, United Kingdom."},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00222-12"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv380"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.6.825"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14232"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2016.05.001"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)53221-X"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2014.05.002"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2011.00957.x"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2015.1034689"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12497"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01034-08"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02448-13"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02061-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02061-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:03:10Z","timestamp":1645477390000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02061-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1128\/AAC.02061-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.02061-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"2017-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02061-17"}}